Hemab Therapeutics (COAG) analyst forecast and price target
Analyst forecast
Consensus of 6 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Rodman & Renshaw | Initiated Coverage | Buy | $56.00 | Oct 12, 2026 |
| Wedbush | Maintained | Outperform | $64.00 from $55.00 | Aug 12, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $60.00 from $52.00 | Aug 11, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $52.00 from $40.00 | Jul 13, 2026 |
| Wedbush | Maintained | Outperform | $55.00 from $42.00 | Jul 13, 2026 |
| Jefferies | Maintained | Buy | $47.00 from $39.00 | Jul 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $40.00 | Jun 26, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $40.00 | Jun 17, 2026 |
| Wedbush | Initiated Coverage | Outperform | $42.00 | May 26, 2026 |
| Evercore ISI Group | Initiated Coverage | Outperform | $50.00 | May 26, 2026 |
| Goldman Sachs | Initiated Coverage | Buy | $36.00 | May 26, 2026 |
| Jefferies | Initiated Coverage | Buy | $39.00 | May 26, 2026 |
Frequently asked questions
What is the price target for COAG stock?
The average 12-month analyst price target for Hemab Therapeutics (COAG) is $60.00, with a high estimate of $64.00 and a low of $56.00, across 3 analysts.
Is COAG a buy, sell, or hold?
Analysts covering Hemab Therapeutics currently average a Buy rating: 6 buy, 0 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for COAG?
The average price target of $60.00 implies 103.39% upside from the last price of $29.50.
What is the latest analyst rating on COAG?
On Oct 12, 2026, Rodman & Renshaw initiated coverage of Hemab Therapeutics at Buy with a price target of $56.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.